Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients ...

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

Given a global shortage of bacillus Calmette-Guérin (BCG) treatment, it has been important to determine whether there are effective alternatives for intermediate-risk non-muscle-invasive bladder ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

The phase 3 CREST trial has been assessing the subcutaneously-administered drug in combination with standard-of-care Bacillus ...